AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 ...

Federal agencies have removed web pages dedicated to DEI programs related to cancer research and other clinical research.